Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta‐analysis
Allergy2017Vol. 72(11), pp. 1597–1631
Citations Over TimeTop 1% of 2017 papers
Sangeeta Dhami, Ulugbek Nurmatov, Stefania Arasi, Tahir Mehmood Khan, Miqdad Asaria, Hadar Zaman, Arnav Agarwal, G. Netuveli, Graham Roberts, Oliver Pfaar, Antonella Muraro, Ignacio J. Ansotegui, Moisés A. Calderón, Cemal Cingi, Stephen R. Durham, Roy Gerth van Wijk, Susanne Halken, Eckard Hamelmann, Peter W. Hellings, Lars Jacobsen, Edward F. Knol, Désirée Larenas‐Linnemann, Sandra Y. Lin, Paraskevi Maggina, Ralph Mösges, Hanneke Oude Elberink, Giovanni Battista Pajno, Ruby Panwankar, Elide A. Pastorello, Martín Penagos, Constantinos Pitsios, Giuseppina Rotiroti, Frans Timmermans, Olympia Tsilochristou, E.‐M. Varga, Carsten B. Schmidt‐Weber, Jennifer Wilkinson, Andrew B. Williams, Margitta Worm, Luo Zhang, Aziz Sheikh
Abstract
AIT is effective in improving symptom, medication, and combined symptom and medication scores in patients with allergic rhinoconjunctivitis while on treatment, and there is some evidence suggesting that these benefits are maintained in relation to symptom scores after discontinuation of therapy.
Related Papers
- → Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: Looking at the published evidence(2012)179 cited
- → Locating and Appraising Systematic Reviews(1997)160 cited
- → Cochrane Skin Group systematic reviews are more methodologically rigorous than other systematic reviews in dermatology(2006)74 cited
- → The allergen specificity of allergen immunotherapy—doubt no more(2019)9 cited
- → Effects of Gaps in Subcutaneous Allergen Immunotherapy and Allergen Extract Components on Systemic Reactions(2025)